Your browser doesn't support javascript.
Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review.
Hernández-Mitre, María Patricia; Tong, Steven Y C; Denholm, Justin T; Dore, Gregory J; Bowen, Asha C; Lewin, Sharon R; Venkatesh, Balasubramanian; Hills, Thomas E; McQuilten, Zoe; Paterson, David L; Morpeth, Susan C; Roberts, Jason A.
  • Hernández-Mitre MP; UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. p.mitre@uq.edu.au.
  • Tong SYC; Victorian Infectious Disease Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Denholm JT; The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Dore GJ; Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia.
  • Bowen AC; Victorian Infectious Disease Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Lewin SR; The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Venkatesh B; Kirby Institute, UNSW Sydney, New South Wales, Australia.
  • Hills TE; Department of Infectious Diseases, Perth Children's Hospital, Perth, WA, Australia.
  • McQuilten Z; Wesfarmers Centre for Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, Nedlands, Australia.
  • Paterson DL; Victorian Infectious Disease Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.
  • Morpeth SC; The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
  • Roberts JA; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia.
Clin Pharmacokinet ; 61(10): 1331-1343, 2022 10.
Статья в английский | MEDLINE | ID: covidwho-2075730
ABSTRACT
The search for clinically effective antivirals against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is ongoing. Repurposing of drugs licensed for non-coronavirus disease 2019 (COVID-19) indications has been extensively investigated in laboratory models and in clinical studies with mixed results. Nafamostat mesylate (nafamostat) is a drug licensed in Japan and Korea for indications including acute pancreatitis and disseminated intravascular coagulation. It is available only for continuous intravenous infusion. In vitro human lung cell line studies with nafamostat demonstrate high antiviral potency against SARS-CoV-2 (half maximal inhibitory concentration [IC50] of 0.0022 µM [compared to remdesivir 1.3 µM]), ostensibly via inhibition of the cellular enzyme transmembrane protease serine 2 (TMPRSS2) preventing viral entry into human cells. In addition, the established antithrombotic activity is hypothesised to be advantageous given thrombosis-associated sequelae of COVID-19. Clinical reports to date are limited, but indicate a potential benefit of nafamostat in patients with moderate to severe COVID-19. In this review, we will explore the pre-clinical, pharmacokinetic and clinical outcome data presently available for nafamostat as a treatment for COVID-19. The recruitment to ongoing clinical trials is a priority to provide more robust data on the safety and efficacy of nafamostat as a treatment for COVID-19.
Тема - темы

Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Pancreatitis / COVID-19 Drug Treatment Тип исследования: Прогностическое исследование / Отзывы Темы: Длинный Ковид Пределы темы: Люди Язык: английский Журнал: Clin Pharmacokinet Год: 2022 Тип: Статья Аффилированная страна: S40262-022-01170-x

Документы, близкие по теме

MEDLINE

...
LILACS

LIS


Полный текст: Имеется в наличии Коллекция: Международные базы данных база данных: MEDLINE Основная тема: Pancreatitis / COVID-19 Drug Treatment Тип исследования: Прогностическое исследование / Отзывы Темы: Длинный Ковид Пределы темы: Люди Язык: английский Журнал: Clin Pharmacokinet Год: 2022 Тип: Статья Аффилированная страна: S40262-022-01170-x